InfuSystems Holdings Inc., also known as INFU, is a leading provider of infusion pumps and related services in the United States and Canada. Founded in 2005, the company is headquartered in Rochester Hills, Michigan, US. INFU is publicly traded on the NYSE under the ticker symbol "INFU". It provides cost-effective solutions to hospitals, oncology practices, and other healthcare providers, while ensuring high-quality patient care and improved clinical outcomes.
InfuSystems services are primarily categorized into two – Integrated Therapy Service (ITS) and Durable Medical Equipment. The ITS program provides electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of a various diseases including colorectal cancer, hepatobiliary cancers, etc. Its Durable Medical Equipment program involves the rental, sale or leasing of infusion pumps to the individuals suffering from painful conditions such as pancreatitis, abdominal pain, etc.
The company has expertise in managing thousands of pumps and millions of disposals each month, along with facilitating third-party payer billing, simplifying the complexities of therapy regimens while maximizing revenue. InfuSystems works closely with healthcare practitioners, patients, and caregivers to deliver high-quality care and ensure customer satisfaction.
InfuSystems proprietary suite of technology solutions, including InfuSystems Mobile, provides a platform for tracking infusion pumps, improved billing accuracy, enhanced practicality, and clinical education. Their innovative smart pump technology enables seamless integration of medical devices with information systems to improve safety and efficiency.
Since its inception, InfuSystems has been known for its commitment to improving patient outcomes. The company continually invests in innovation and technology to enhance its product suite and expand its service offerings. This dedication to better patient care and hospital productivity has positioned InfuSystems as a reliable and respected name in the healthcare sector.
Under the leadership of CEO Richard DiIorio, who took over in 2017, InfuSystems has shown continuous growth, with impressive financial results. The company has robust plans for future growth, building on a solid foundation of quality service, innovation, and a commitment to improving patient care delivery. However, like other healthcare providers, InfuSystems is grappling with the effects of the COVID-19 pandemic, though its diversified revenue stream and innovative technological solutions are expected to help it navigate these challenges effectively.
In conclusion, InfuSystems Holdings, Inc, through its innovative service offerings and commitment to quality patient care, sets itself apart in the healthcare sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
InfuSystem Holdings, Inc. (NYSE:INFU) saw its shares drop by 1.8% in Wednesday trading, closing at $12.24. Despite the dip, B. Riley reiterated a "Buy" rating and increased its price target to $20, contributing to a "Moderate Buy" consensus among analysts. The company also announced a $20 million share repurchase program, indicating management believes the stock is undervalued.
B. Riley has increased its target price for InfuSystem Holdings Inc. (INFU) to $20, up from its previous target of $12. This revision suggests a positive outlook from the analyst firm regarding the company's future stock performance.
InfuSystem Holdings, Inc. reported record quarterly revenue and improved adjusted EBITDA, driven by strong oncology and wound care segments, despite headwinds from a restructured GE Healthcare contract and increased operating expenses. The company reaffirmed its 2026 revenue growth guidance and aims for continued margin expansion, positioning itself as a disciplined healthcare services provider focused on strategic growth and conservative leverage.
InfuSystems Holdings reported record Q2 2026 revenue of $36.9 million, a 2.6% year-over-year increase, with adjusted EBITDA up 7.6% to $8.6 million. This growth was driven by a strong performance in oncology revenue, exceeding $20 million, and a significant 154% surge in wound care revenue, particularly from lymphedema compression devices. The company anticipates continued annual revenue growth of 6% to 8% for the second half of 2026, maintaining adjusted EBITDA margins in the low to mid-20% range, supported by a strong financial position and strategic partnerships.